4-(2-bromo-6-pyrrolidine-1-yl-pyridine-4-sulphonyl)-phenylamine | 231286-79-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(2-bromo-6-pyrrolidine-1-yl-pyridine-4-sulphonyl)-phenylamine
• 英文别名: 4-(2-Bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine；4-(2-bromo-6-pyrrolidin-1-ylpyridin-4-yl)sulfonylaniline
• CAS: 231286-79-6
• 化学式: C₁₅H₁₆BrN₃O₂S
• 分子量: 382.281
• InChiKey: WDFMDNUTOSLOPW-UHFFFAOYSA-N

物化性质

• 熔点：
  216 °C (decomp)
• 沸点：
  632.4±55.0 °C(Predicted)
• 密度：
  1.566±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  84.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl acetate n-hexane 、 4-(2-bromo-6-pyrrolidine-1-yl-pyridine-4-sulphonyl)-phenylamine 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 、 水 为溶剂， 生成 4-(2-pyrrolidin-1-yl-pyridine-4-sulfonyl)-phenylamine
  参考文献：
  名称：

  Benzosulfone derivatives

  摘要：

  本发明涉及一般式为##STR1##的新化合物，其中R.sup.1为氢；R.sup.2为氢，三氟甲基或较低的烷基；R.sup.3为氢或氨基；或者R.sup.1和R.sup.2或R.sup.3和R.sup.2一起取--CH.dbd.CH--CH.dbd.CH--；Z为嘧啶-4-基，吡啶-4-基，吡啶-2-基或苯基；R.sup.4，R.sup.5各自独立地为氢，较低烷基，三氟甲基，卤素，较低烷氧基，氰基，氨基，较低烷基氨基，二较低烷基氨基，哌嗪基，吗啉基，吡咯烷基，乙烯基，C.sub.3 -C.sub.6环烷基，C.sub.3 -C.sub.6环烯基，叔丁基乙炔基，羟基烯基，苯基乙炔基，萘基，噻吩基或苯基，可以被卤素，较低烷氧基，较低烷基，三氟甲基或硝基取代，或者为--NH(CH.sub.2).sub.n NR.sup.6 R.sup.7，--N(CH.sub.3)(CH.sub.2).sub.n NR.sup.6 R.sup.7，--NH(CH.sub.2).sub.n -吗啉-4-基或--NH(CH.sub.2).sub.n OH的基团；n为2-4，R.sup.6和R.sup.7各自独立地为氢或较低烷基，以及它们的药用可接受盐。已发现，式I的化合物具有对5HT-6受体的选择性亲和力。

  公开号：

  US05990105A1
• 作为产物：
  描述：

  2,6-二溴-4-硝基吡啶氮氧化物 在 三溴化磷 、 铁粉 、 氯化铵 、 间氯过氧苯甲酸 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 24.5h， 生成 4-(2-bromo-6-pyrrolidine-1-yl-pyridine-4-sulphonyl)-phenylamine
  参考文献：
  名称：

  Influence of the 5-HT₆ Receptor on Acetylcholine Release in the Cortex:  Pharmacological Characterization of 4-(2-Bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a Potent and Selective 5-HT₆ Receptor Antagonist

  摘要：

  A small series of aryl pyridyl sulfones has been prepared and investigated for its 5-HT6 receptor binding properties. Thereof, pyrrolidinyl derivative 11 proved to be a very potent (pK(i) 9) and selective 5-HT6 receptor antagonist. By means of in vivo microdialysis in the frontal cortex and a passive avoidance paradigm, where 11 reversed a scopolamine induced retention deficit, a functional correlation between 5-HT6 receptors and cholinergic neurotransmission could be shown, supporting the therapeutic potential of 5-HT6 receptors in the treatment of cognitive deficits.

  DOI：

  10.1021/jm021085c

文献信息

• NOVEL SUBSTITUTED-1-H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
  申请人：Seong Churlmin

  公开号：US20090203708A1

  公开（公告）日：2009-08-13

  Disclosed herein are novel substituted-1H-quinazoline-2,4-dione derivatives, a preparation method thereof, and a pharmaceutical composition containing the same. The novel substituted-1H-quinazoline-2,4-dione derivatives are excellent in binding affinity and selectivity for 5-HT6 receptors over other receptors, inhibit serotonin(5-HT)-stimulated cAMP accumulation, and disrupt apomorphine(2 mg/kg, i.p.)-induced hyperactivity in rats. Thanks to these effects, the derivatives are useful in the treatment of 5-HT6 receptor-related central nervous system diseases.

  本文披露了一种新型的取代-1H-喹唑啉-2,4-二酮衍生物，其制备方法以及含有该衍生物的药物组合物。这种新型的取代-1H-喹唑啉-2,4-二酮衍生物在与其他受体相比对5-HT6受体的结合亲和力和选择性方面表现出色，抑制5-羟色胺（5-HT）刺激的cAMP积累，并破坏大鼠中阿波莫啡（2 mg/kg，i.p.）诱导的过度活动。由于这些效果，这些衍生物在治疗与5-HT6受体相关的中枢神经系统疾病中非常有用。
• SUBSTITUTED METHYL AMINES, SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS, METHODS FOR PRODUCTION AND USE THEREOF
  申请人：Ivachtchenko Alexandre Vasilievich

  公开号：US20130267536A1

  公开（公告）日：2013-10-10

  The present invention relates to novel substituted methyl-amines, serotonin 5-HT 6 receptor antagonists, to active components, pharmaceutical compositions, method for prophylaxis and treatment of CNS diseases and “molecular tools”, in which novel substituted methyl-amines represent compounds of the general formula 1 and their crystalline forms and pharmaceutically acceptable salts, wherein: W represents benzene, naphthalene, indolizine, quinoline or oxazole cycle; R1=H, F, Cl; R2 represents hydrogen, fluoro, methyl, phenyl, thienyl, furan-2-yl, pyridyl, piperazin-1-yl or 4-methylpiperazin-1-yl; R3 represents cyclopropyl or optionally substituted methyl; with the exception of the compounds in which W simultaneously represents oxazole cycle and R2=phenyl or pyridyl.

  本发明涉及新型取代甲基胺，血清素5-HT6受体拮抗剂，活性成分，药物组合物，预防和治疗中枢神经系统疾病的方法和“分子工具”，其中新型取代甲基胺代表一般式1的化合物及其结晶形式和药用可接受盐， 其中：W代表苯，萘，吲哚啉，喹啉或噁唑环；R1=H，F，Cl；R2代表氢，氟，甲基，苯基，噻吩基，呋喃-2-基，吡啶基，哌嗪-1-基或4-甲基哌嗪-1-基；R3代表环丙基或可选择取代的甲基；除了W同时代表噁唑环且R2=苯基或吡啶基的化合物。
• SUBSTITUTED 8-SULFONYL-2,3,4,5-TETRAHYDRO-1H-GAMMA-CARBOLINES, LIGANDS AND PHARMACEUTICAL COMPOSITION; METHOD FOR THE PRODUCTION AND USE OF SAME
  申请人：Ivashchenko Andrey Alexandrovich

  公开号：US20120071493A1

  公开（公告）日：2012-03-22

  The invention relates to novel substituted 8-sulfonyl-2,3,4,5-tetrahydro-1H-γ-carbolines of the general formula 1 and their pharmaceutically acceptable salt—ligands exhibiting biological activity simultaneously towards alpha-adrenoceptors, dopamine receptors, histamine receptors, imidazoline receptors, sigma receptors, norepinefrine receptors, serotonin receptors, to active components, pharmaceutical compositions, comprising as an active component novel ligands, to novel medicaments intended for treatment of conditions and diseases of central nervous system. In the general formula 1 R 1 represents a substituent selected from hydrogen, optionally substituted C 1 -C 3 alkyl or C 1 -C 4 alkyloxycarbonyl; R 2 represents a cyclic system substituent selected from hydrogen, optionally substituted C 1 -C 3 alkyl, optionally substituted C 2 -C 3 alkenyl or substituted sulfonyl; R 3 represents optionally substituted aryl or substituted amino group.

  该发明涉及一种新型的取代的8-磺酰基-2,3,4,5-四氢-1H-γ-咔啉的化合物，其一般式为1，以及它们的药用盐——配体，同时对α-肾上腺素受体、多巴胺受体、组胺受体、咪唑啉受体、西格玛受体、去甲肾上腺素受体、5-羟色胺受体表现出生物活性的配体，以及作为活性成分的新型配体组成的药物组合物，用于治疗中枢神经系统疾病和病症的新型药物。在一般式1中，R1代表从氢、可选取代的C1-C3烷基或C1-C4烷氧羰基中选择的取代基；R2代表从氢、可选取代的C1-C3烷基、可选取代的C2-C3烯基或取代的磺酰基中选择的环系统取代基；R3代表可选取代的芳基或取代的氨基团。
• INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS
  申请人：Adamed sp. z o.o.

  公开号：EP3530651A1

  公开（公告）日：2019-08-28

  The invention relates to new 4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-indoles and 4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-benzimidazoles represented by formula (I), wherein all symbols and variables are as defined in the description. The compounds can find use in a method of prevention and/or treatment of diseases selected from the group consisting of Alzheimer's disease, Parkinson's disease, Levy body dementia, dementia-related psychosis, schizophrenia, delusional syndromes and other psychotic conditions related and not related to taking psychoactive substances, depression, anxiety disorders of various aetiology, sleep disorders of various aetiology.

  该发明涉及新的4-(哌嗪-1-基)-2-(三氟甲基)-1H-吲哚和4-(哌嗪-1-基)-2-(三氟甲基)-1H-苯并咪唑，其化学式如下所示（I），其中所有符号和变量的定义如描述中所示。这些化合物可用于预防和/或治疗从阿尔茨海默病、帕金森病、莱文体痴呆、与痴呆相关的精神病、精神分裂症、妄想综合征以及与服用精神活性物质有关和无关的其他精神病症状、抑郁症、不同病因的焦虑症和不同病因的睡眠障碍等疾病的预防和/或治疗方法中。
• NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
  申请人：Seong Churlmin

  公开号：US20100035866A1

  公开（公告）日：2010-02-11

  The present invention relates to compounds of substituted-1,1-dioxo-benzo[1,2,4]thiadiazin-3-ones acting as a 5HT6 receptor antagonist, a preparation method thereof, and a pharmaceutical composition containing the same for treatment of the central nervous system disorders. The compounds of substituted-1,1-dioxo-benzo[1,2,4]thiadiazin-3-ones according to the present invention have excellent binding affinity for the 5HT6 receptor and excellent selectivity for the 5HT6 receptor over other receptors. Also, the compounds reverse a disruption of PPI by apomorphine and don't show rotatod deficit in mice. Therefore the compounds according to the present invention may be valuably used for treatment of a 5HT6 receptor relating disorders.

  本发明涉及一种替代-1,1-二氧代苯并[1,2,4]噻二嗪-3-酮化合物，其作为5HT6受体拮抗剂，以及其制备方法和含有该化合物的用于治疗中枢神经系统疾病的药物组合物。根据本发明的替代-1,1-二氧代苯并[1,2,4]噻二嗪-3-酮化合物具有出色的与5HT6受体的结合亲和力，并且对5HT6受体具有优异的选择性，而不会影响其他受体。此外，这些化合物可以逆转阿波莫啶对PPI的干扰，并且在小鼠中不显示旋转缺陷。因此，根据本发明的化合物可以有价值地用于治疗与5HT6受体相关的疾病。